Phase 1b/2a immuno-oncology trial of HyLeukin-7 in combination with atezolizumab in patients with anti-PD-(L)1 naïve or refractory high-risk skin cancers.
Phase of Trial: Phase I/II
Latest Information Update: 04 May 2018
At a glance
- Drugs Atezolizumab (Primary) ; GX I7 (Primary)
- Indications Skin cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors NeoImmuneTech
- 04 May 2018 New trial record
- 01 May 2018 According to the NeoImmuneTech media release, this trial will be led by NIT and the Immune Oncology Network.
- 01 May 2018 According to the NeoImmuneTech media release, this trial is anticipated to start in the second half of 2018.